Tag Archive for: finance

cash machine

The Mainz-based vaccine developer is making progress in its transformation into an oncology company. But its quarterly report also shows how much work remains: Pumitamig is at the center of clinical development, while other advanced candidates still need to confirm their results. In the meantime, BioNTech is also facing setbacks in its mRNA cancer programs. The collaboration with Bristol Myers Squibb has become a major pillar of revenue — although primarily through contractual payments rather than drug sales.

NRW Science Minister Ina Brandes, Prof. Dr. Michael Hallek, director of the Department I of Internal Medicine and the Center for Integrated Oncology at University Hospital Cologne, and NRW Minister-President Hendrik Wüst
Photo: State of North Rhine-Westphalia / Marius Becker

North Rhine-Westphalia (NRW), a state located in the North-West of Germany, is investing €200 million to connect university hospitals in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne and Münster, as well as the Technical University Dortmund in an AI network for cancer medicine.

wall street sign

Sweden’s Hansa Biopharma has confidentially filed paperwork with the U.S. Securities and Exchange Commission for a potential initial public offering of American depositary shares.

GSK's Stevenage R&D site, UK.

GSK has announced plans to shut its UK R&D headquarters in Stevenage, UK, moving operations north to a new site in Cambridge, while also announcing a company-wide programme to reduce annual costs by £1.9 billion (€2.2 billion).

jackpot cash machine

Abivax has raised $920m (€807m) in gross proceeds through a US public offering, only days after new obefazimod data helped calm investor concerns over the drug’s safety profile in ulcerative colitis.

plotting financial strategy

UK immunotherapy developer Scancell has confirmed talks to acquire Nasdaq-listed Neuphoria Therapeutics, in a move that could give the Oxford-based biotech a faster route to US public markets.

Capital is tight and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures.